Loading...
Loading...
NRSN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,287.0K |
| Operating I/L | -3,287.0K |
| Other Income/Expense | 337.0K |
| Interest Income | 0.0K |
| Pretax | -2,950.0K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -2,950.0K |
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company specializing in the discovery and development of treatments for neurodegenerative diseases. Its lead product, PrimeC, is an oral formulation that has completed Phase IIa clinical trials for amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.
